MedTrace Logo

Mindfulness-Based Therapy for Brain Tumour Survivors

NCT02792608 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2019-06-07

No results posted yet for this study

Summary

Brain Tumour (BT) survivors struggle with disabling physical, emotional, cognitive and psychosocial sequelae. Unfortunately, to-date there has been very limited research into rehabilitative interventions for this population. With 55,000 BT survivors in Canada alone1, access to effective, evidence-based rehabilitative treatment that would improve BT survivors' quality of life (QOL) and capacity to cope is a necessity. Mindfulness-Based Therapy's (MBTs) are emerging as a potential treatment to address this need. MBTs are group-based psychological treatments for coping with illness or disability, with the goal of improving psychological wellbeing. Recent studies have begun to suggest a role for MBTs in addressing symptom burden and QOL in the acquired brain injury (ABI) population, a heterogeneous population that includes survivors of stroke and traumatic brain injury, as well as BT survivors. High quality research including within-subject controlled trials, are needed to demonstrate whether MBTs can provide efficacious, accessible and cost-effective treatment to improve the lives of BT survivors.

Conditions

  • Brain Tumour
  • Depressive Symptoms
  • Survivors

Interventions

BEHAVIORAL

Mindfulness-based Therapy

MBT will be delivered in group format, 135 minutes per week, for 5 consecutive weeks with 10-20 participants per group.

Sponsors & Collaborators

  • Brain Tumour Foundation of Canada

    collaborator UNKNOWN

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Steven Selchen, MD MSt FRCPC · Sunnybrook Health Sciences Centre

  • Janet Ellis, MB MD FRCPC · Sunnybrook Health Sciences Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2018-11-23
Completion
2018-11-23

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02792608 on ClinicalTrials.gov